Industry To FDA: Generic Drug Review Delays Increase Healthcare Costs

June 18, 2015 at 7:11 PM

Stakeholders urged FDA Monday (June 15) to address the increasing length of generic drug review times, with some saying the delays have cost the U.S. health care system more than $3 billion in the last year and a half alone and may cause companies to direct their manufacturing resources toward higher-priced drugs.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.